StockData

Astrotech vs Co-Diagnostics

ASTC and CODX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASTC and CODX compare

Astrotech is the larger company, worth 6.4 times as much as Co-Diagnostics ($7.8M against $1.2M).

Astrotech grew revenue faster over the last twelve months (−13.0% versus −28.1% for Co-Diagnostics).

Astrotech keeps more of each dollar of sales as profit, with a net margin of −1580% compared with −6523% at Co-Diagnostics.

Astrotech scores higher on the StockData Score (8 against 7 for Co-Diagnostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASTCCODX
Size and price
Market cap$7.8M$1.2M
Share price$3.89$0.196
Change, 1 year18.6%−98.0%
Change, 5 years−84.0%−99.9%
Employees28115
StockData Score
Total score8 (better)7
Valuation score3 (better)1
Growth score01 (better)
Performance score00
Health score55
Dividend score00
Valuation
P/S8.6×1.7× (better)
P/B0.5×0.1× (better)
FCF yield−183% (better)−2242%
Fair value$8.84–
Margin of safety56.0%–
Growth
Revenue growth (TTM)−13.0% (better)−28.1%
Revenue growth, 5Y average22.3% (better)−61.6%
Profitability
Gross margin23.8%43.5% (better)
Operating margin−1549% (better)−6788%
Net margin−1580% (better)−6523%
FCF margin−1570% (better)−3808%
Return on equity−75.4% (better)−176%
Return on invested capital−256%−213% (better)
Financial health
Debt / equity0.000.00
Current ratio7.06 (better)1.81
Altman Z-score−18.46−17.42 (better)
Piotroski F-score2 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions8.6%9.5%
Held by insiders16.6%14.7%
Short interest, % of float3.5%18.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.